Sign up Australia
Proactive Investors - Run By Investors For Investors

Analytica expands clinical indication for its unique pelvic floor exercise technology

PeriCoach system is now indicated for urinary incontinence, sexual wellness and pelvic organ prolapse.
PeriCoach System demostration
No other system on the market has this capability

Analytica Limited (ASX:ALT) has received clearance from the Australian Therapeutic Goods Administration for the expanded clinical indication for its PeriCoach System to assist in the conservative treatment of Pelvic Organ Prolapse (POP).

The PeriCoach system with its patent protected force sensing technology assists women to properly perform pelvic floor exercises.

The expanded clinical indication for PeriCoach now includes targeted resolution of symptoms for mild to moderate POP, urinary incontinence and sexual wellness.

Pelvic organ prolapse is a common and serious condition

Data suggests that 50% of women that have given birth have some degree of POP and half of women over 50 complain of prolapse symptoms.

Estimates state women have a lifetime risk of up to 12% of undergoing a surgical intervention, with a re-operation rate of nearly 20%.

Each surgical intervention in the U.S. is estimated to cost between USD$10,000- USD$20,000.

As the population continues to age and awareness of the condition grows, it is projected that the number of women with POP will increase up to 46%.

Potential sale of the technology to a multinational

Analytica chairman Dr Michael Monsour said: “This clearance from the TGA is significant in that the PeriCoach system is indicated for the most common conditions stemming from a weak pelvic floor: urinary incontinence, sexual wellness, and pelvic organ prolapse.

“No other system on the market has this capability.

“This additional capability adds substantial value and progresses the sale of the company and PeriCoach system to a multinational”.

View full ALT profile View Profile

Analytica Ltd Timeline

Newswire
January 18 2016
Newswire
October 08 2014
Newswire
September 29 2014

Related Articles

Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
lungs
September 25 2018
The drug developer had originally to recruit 80 people for the second part of its phase II study of its SNG001 treatment, but it will now assess 120 patients
cancer cells in blood
July 17 2018
It’s been a tricky year for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use